Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.50 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.51 |
| ▸ | WNT3A | P56704 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691373 | 0.98 | LMNA (0.59) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL16419608 | 0.81 | ALDH1A1 (0.65) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL992300 | 0.80 | ALDH1A1 (0.67) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL994292 | 0.79 | ALDH1A1 (0.57) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL2516127 | 0.78 | LMNA (0.75) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL170394 | 0.78 | ALDH1A1 (0.69) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11663088 | 0.77 | HDAC1 (0.59) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL4135291 | 0.77 | ALDH1A1 (0.57) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL16404278 | 0.77 | ALDH1A1 (0.57) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL13518261 | 0.77 | ALDH1A1 (0.57) | LMNAALDH1A1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957227-B2 | Preparation of Duloxetine® hydrochloride using optically active methylhydroxylaminopropanol compound as an intermediate | SCI PHARMTECH, INC. (TW) | 2015-02-17 | — | — | US | disclosed |
| EP-2386549-B1 | Process for preparing (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine by using an optically active methylhydroxylaminopropanol compound as intermediate | SCI PHARMATECH INC (TW) | 2014-03-19 | — | — | EP | disclosed |
| US-20140005414-A1 | PREPARATION OF DULOXETINE HYDROCHLORIDE USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS AN INTERMEDIATE | SCI PHARMTECH, INC. (TW) | 2014-01-02 | — | — | US | disclosed |
| US-8614336-B2 | Process for preparing N-methyl-N-hydroxyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine derivative | SCI PHARMTECH, INC. (TW) | 2013-12-24 | — | — | US | disclosed |
| US-8530674-B2 | Process for preparing (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine by using optically active methylhydroxylaminopropanol compound as intermediate | SCI PHARMTECH, INC. (TW) | 2013-09-10 | — | — | US | disclosed |
| US-8420832-B2 | Optically active methylhydroxylaminopropanol derivative and its use as intermediate for preparation of (S)-(-)-3-methylamino-1-(-2-thienyl)propan-1-ol | SCI PHARMTECH, INC. (TW) | 2013-04-16 | — | — | US | disclosed |
| US-20120190869-A1 | OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL DERIVATIVE AND ITS USE AS INTERMEDIATE FOR PREPARATION OF (S)-(-)-3-METHYLAMINO-1-(-2-THIENYL)PROPAN-1-OL | SCI PHARMTECH, INC. (TW) | 2012-07-26 | — | — | US | disclosed |
| US-8168805-B2 | Optically active methylhydroxylaminopropanol compound and its use as intermediate for preparation of (S)-(−)-3-methylamino-1-(2-thienyl)propan-1-ol | SCI PHARMTECH, INC (TW) | 2012-05-01 | — | — | US | disclosed |
| US-8148549-B2 | Preparation of (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl) propylamine using optically active methylhydroxylaminopropanol compound as an intermediate | SCI PHARMTECH, INC. (TW) | 2012-04-03 | — | — | US | disclosed |
| EP-2228372-B1 | Process for Preparing (S)-(+)-N-Methyl-3-(1-Naphthyloxy)-3-(2-Thienyl-Propylamine by using Optically Active Methylhydroxylaminopropanol Compound as an Intermediate | SCI PHARMATECH INC (TW) | 2012-02-29 | — | — | EP | disclosed |
| EP-2386549-A1 | Process for preparing (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine by using an optically active methylhydroxylaminopropanol compound as intermediate | SCI Pharmatech, Inc. (TW) | 2011-11-16 | — | — | EP | disclosed |
| US-20110275835-A1 | PROCESS FOR PREPARING (S)-(+)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE BY USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS INTERMEDIATE | SCI PHARMTECH, INC. (TW) | 2011-11-10 | — | — | US | disclosed |
| US-8038648-B2 | Injection device and method | INNOVACELL BIOTECHNOLOGIE GMBH (AT) | 2011-10-18 | — | — | US | disclosed |
| US-7829731-B2 | Methylhydroxylaminopropanol derivative and its use as intermediate for preparation of 3-methylamino-1-(2-thienyl)propan-1-OL | SCI PHARMTECH, INC. (TW) | 2010-11-09 | — | — | US | disclosed |
| US-20100234620-A1 | PROCESS FOR PREPARING N-METHYL-N-HYDROXYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE DERIVATIVE | SCI PHARMTECH, INC. (TW) | 2010-09-16 | — | — | US | disclosed |
| US-20100234619-A1 | PREPARATION OF (S)-(+)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL) PROPYLAMINE USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL DERIVATIVE AS AN INTERMEDIATE | SCI PHARMTECH, INC. (TW) | 2010-09-16 | — | — | US | disclosed |
| EP-2228372-A1 | Process for Preparing (S)-(+)-N-Methyl-3-(1-Naphthyloxy)-3-(2-Thienyl-Propylamine by using Optically Active Methylhydroxylaminopropanol Compound as an Intermediate | SCI Pharmatech, Inc. (TW) | 2010-09-15 | — | — | EP | disclosed |
| US-20090112000-A1 | METHYLHYDROXYLAMINOPROPANOL DERIVATIVE AND ITS USE AS INTERMEDIATE FOR PREPARATION OF 3-METHYLAMINO-1-(2-THIENYL)PROPAN-1-OL | SCI PHARMTECH, INC. (TW) | 2009-04-30 | — | — | US | disclosed |
| US-20090112001-A1 | OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL DERIVATIVE AND ITS USE AS INTERMEDIATE FOR PREPARATION OF (S)-(-)-3-METHYLAMINO-1-(2-THIENYL)PROPAN-1-OL | SCI PHARMTECH, INC. (TW) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005414-A1 | PREPARATION OF DULOXETINE HYDROCHLORIDE USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS AN INTERMEDIATE | ADRA1A, ADRA2A, ADRB1 | GAA 1065/4885HDAC1 1756/4885LMNA 761/4885 |
| US-20100234620-A1 | PROCESS FOR PREPARING N-METHYL-N-HYDROXYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE DERIVATIVE | PNMT, NNMT, HNMT | GAA 3566/4885HDAC1 1615/4885LMNA 676/4885 |
| US-20090112000-A1 | METHYLHYDROXYLAMINOPROPANOL DERIVATIVE AND ITS USE AS INTERMEDIATE FOR PREPARATION OF 3-METHYLAMINO-1-(2-THIENYL)PROPAN-1-OL | PNMT, HPD, MSMO1 | GAA 2909/4885HDAC1 2980/4885LMNA 1001/4885 |
| US-20100234619-A1 | PREPARATION OF (S)-(+)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL) PROPYLAMINE USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL DERIVATIVE AS AN INTERMEDIATE | PNMT, HNMT, BHMT2 | GAA 3740/4885HDAC1 1711/4885LMNA 538/4885 |
| US-20110275835-A1 | PROCESS FOR PREPARING (S)-(+)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE BY USING OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL COMPOUND AS INTERMEDIATE | PNMT, HNMT, INMT | GAA 2714/4885HDAC1 2519/4885LMNA 710/4885 |
| US-20120190869-A1 | OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL DERIVATIVE AND ITS USE AS INTERMEDIATE FOR PREPARATION OF (S)-(-)-3-METHYLAMINO-1-(-2-THIENYL)PROPAN-1-OL | THOP1, HPD, PNMT | GAA 1986/4885HDAC1 3170/4885LMNA 990/4885 |
| US-20090112001-A1 | OPTICALLY ACTIVE METHYLHYDROXYLAMINOPROPANOL DERIVATIVE AND ITS USE AS INTERMEDIATE FOR PREPARATION OF (S)-(-)-3-METHYLAMINO-1-(2-THIENYL)PROPAN-1-OL | THOP1, HPD, PNMT | GAA 1862/4885HDAC1 3574/4885LMNA 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.